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Abstract
Purpose Hesperidin, a glycoside flavonoid, is thought to act
as an anti-cancer agent, since it has been found to exhibit both
pro-apoptotic and anti-proliferative effects in several cancer
cell types. The mechanisms underlying hesperidin-induced
growth arrest and apoptosis are, however, not well under-
stood. Here, we aimed to investigate the anti-proliferative
and apoptotic effects of hesperidin on non-small cell lung
cancer (NSCLC) cells and to investigate the mechanisms
involved.
Methods The anti-proliferative and apoptotic effects of hes-
peridin on two NSCLC-derived cell lines, A549 and NCI-
H358, were determined using a WST-1 colorimetric assay, a
LDH cytotoxicity assay, a Cell Death Detection assay, an
AnnexinV-FITC assay, a caspase-3 assay and a JC-1 assay,
respectively, all in a time- and dose-dependent manner. As a
control, non-cancerous MRC-5 lung fibroblasts were includ-
ed. Changes in whole genome gene expression profiles were
assessed using an Illumina Human HT-12v4 beadchip micro-
array platform, and subsequent data analyses were performed
using an Illumina Genome Studio and Ingenuity Pathway
Analyser (IPA).
Results We found that after hesperidin treatment, A549 and
NCI-H358 cells exhibited decreasing cell proliferation and
increasing caspase-3 and other apoptosis-related activities, in
conjunction with decreasing mitochondrial membrane poten-
tial activities, in a dose- and time-dependent manner. Through
a GO analysis, by which changes in gene expression profiles
were compared, we found that the FGF and NF-κB signal
transduction pathways were most significantly affected in
the hesperidin treated NCI-H358 and A549 NSCLC cells.
Conclusions Our results indicate that hesperidin elicits an
in vitro growth inhibitory effect on NSCLC cells by modulat-
ing immune response-related pathways that affect apoptosis.
When confirmed in vivo, hesperidin may serve as a novel anti-
proliferative agent for non-small cell lung cancer.
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Abbreviations
EF Nucleosomal enrichment factor
FBS Fetal bovine serum
FGF Fibroblast growth factor
FITC Fluorescein ısothiocyanate
IPA Ingenuity pathway analysis
LDH Lactate dehydrogenase
MEM-α Eagle’s minimum essential medium
NF-kB Nuclear factor kappa B
NSCLC Non-small cell lung cancer
PS Phosphatidylserine
RPMI-1640 Roswell Park Memorial Institute-1640
1 Introduction
Worldwide, lung cancer is the leading cause of cancer death
among both women andmen, with an estimated number of more
than 1000,000 deaths each year [1]. Based on their tendencies to
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metastasize and their responses to existing therapies, lung cancers
can be divided into two major classes, i.e., non-small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC) [2]. NSCLC
accounts for ~80 % of all lung cancer cases, with adenocarcino-
ma being the primary subtype [3]. NSCLC is less responsive to
chemotherapy than SCLC and, as a consequence, NSCLC is the
main focus of current research through which several new ther-
apeutic drugs are being investigated [4–6]. The overall prognosis
of lung cancer is poor, which is primarily due to the fact that the
diagnosis is frequently made late and/or at an advanced stage [7].
Although 70 % of the newly diagnosed patients present with
locally advanced or metastatic lung cancers that require systemic
treatment, currently available systemic chemotherapies and mo-
lecular targeted therapies have their limitations due to dose-
dependent toxicities and the acquisition of drug resistancies
[6–8]. In order to develop novel effective treatment strategies
for lung cancer, several recent studies have been focusing on
dietary agents including nutraceuticals, which are non-toxic,
cost-effective and physiologically available [9–11].
Flavonoids are polyphenolic secondary metabolites that are
abundantly present in vegetables, fruits and beverages such as tea
and wine [12–13]. In particular, citrus flavonoids have been
found to exhibit anti-carcinogenic and anti-inflammatory proper-
ties [14–16] and, therefore, these flavonoids may serve as poten-
tial chemotherapeutic agents [14, 17, 18]. In addition, they have
been shown to exhibit low or no cytotoxicities towards normal
cells [16]. Citrus flavonoids have also been found to exert syn-
ergistic effects with various known chemotherapeutic agents
[17]. Hesperedin is a flavanone glycoside that is found abundant-
ly in oranges and lemons [19–20] and has a wide range of prop-
erties including anti-inflammatory, analgesic, anti-fungal, anti-
viral and anti-cancer properties [21–26]. Hesperidin has also
been found to inhibit cell cycle progression in human pancreatic
cells [27] and to contribute to the intracellular anti-oxidant de-
fense system by acting as an agent against superoxide, singlet
oxygen and hydroxyl radicals [28].
The effects of hesperidin on the prevention and treatment
of diseases, including cancer, have recently been a focus of
attention due to its pharmacological properties [29]. Although
hesperidin is thought to exhibit anti-proliferative effects
against many cancer types, its exact mode of action is not well
understood [30–31]. Hence, we set out to investigate whether
hesperidin has anti-proliferative and/or apoptotic effects in
NSCLC cells, and to examine its genome-wide effects on
(changes in) gene expression.
2 Materials and methods
2.1 Cells and culture conditions
The NCI-H358 bronchioalveolar carcinoma and MRC-5 lung
fibroblast cell lines were obtained from the American Type
Culture Collection (ATCC; Manassas, VA, USA). The A549
adenocarcinoma cell line was kindly provided by Dr.Yusuf
Baran (Department of Molecular Biology and Genetics,
IYTE). The NCI-H358 cell line was cultured in RPMI-1640
medium supplemented with 1 % penicillin/streptomycin and
10 % fetal bovine serum (FBS) at 37 °C in 5 % CO2. The
A549 andMRC-5 cell lines were cultured inMEM-αmedium
supplementedwith 1% penicillin/streptomycin and 10% FBS
at 37 °C in 5 % CO2.
2.2 Reagents and assay kits
All cell culture reagents were purchased from GIBCO Life
Technologies (Thermo Fisher Scientific, USA). Hesperidin
was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The WST-1, Cell Death Detection ELISA PLUS
andHigh Pure RNA Isolation kits were purchased fromRoche
Life Sciences (Germany). The CytoTox 96RNon-Radioactive
Cytotoxicity Assay kit was purchased from Promega
Corporation (Madison, WI, USA). The FITC Annexin V
Apoptosis Detection kit was purchased from BD
Biosciences (Franklin Lakes, NJ, USA). The Caspase-3 col-
orimetric kit was purchased from BioVision Research
Products (Milpitas, CA, USA). The JC-1 Mitochondrial
Membrane Potential Detection kit was purchased from
Cayman Chemical (Ann Arbor, MI, USA). Human whole
genome gene expression profiling was performed using
Illumina Human HT-12v4 beadchips and microarray reagents
(San Diego, CA, USA).
2.3 Cell growth and cytotoxicity assays
A549, NCI-H358 and MRC-5 cells were seeded at a density
of 1 × 104/ml (0,1 ml/well) in 96-well microtiter plates and
allowed to adhere and grow for 24 h. Cells in log phase were
used for subsequent drug treatment. Hesperidin was dissolved
in DMSO as a 100mM stock solution and stored as aliquots in
tightly sealed vials at −20 °C. Working solutions were pre-
pared by serial dilution of the stock solution with culture me-
dium. After the initial 24 h incubation period, cells were treat-
ed with increasing concentrations of hesperidin (5–50μM) for
24, 48 and 72 h. AWST-1 colorimetric cell proliferation assay
(Roche Life Sciences, Germany) was performed to assess its
effects on cell viability. After each incubation period, cells
were treated with 10 μl 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt
(WST-1) for 4 h. Subsequently, color development was mea-
sured at 450 nm using a Multiscan ELISA reader (Thermo
Fisher Scientific, Germany). Cells not treated with hesperidin
were used as negative controls.
The cytotoxic effect of hesperidin was colorimetrically de-
termined using a CytoTox 96R Non-Radioactive Cytotoxicity
Assay kit (Promega; Madison, WI, USA). To this end, cells
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were treated as described above for the WST-1 assay and the
culture media (10 μl) were transferred to a 96-well microtiter
plate. Subsquently, the levels of lactate dehydrogenase (LDH)
were determined by adding a freshly prepared substrate mix,
incubation in the dark at room temperature for 30 min, addi-
tion of 50 μl STOP Solution and measurement of the optical
density at 490 nm using a microplate reader (Bio-Rad;
Hercules, CA, USA). The measurements were repeated in
three independent experiments.
2.4 Apoptotic nucleosomal DNA release assay
The Cell Death Detection ELISA PLUS assay (CDDE; Roche
Life Sciences, Germany) is a photometric enzyme-
immunoassay for the quantitative in vitro determination of
DNA in cytoplasmic histone-associated DNA fragments
(mono- and oligo-nucleosomal), which is a measure of apo-
ptosis. Color development of the samples was taken as an
enrichment factor of DNA fragments in the cell supernatant
relative to untreated cells. Briefly, 1 × 104/ml (0,1 ml/well)
A549 and NCI-H358 cells (treated with 5–50 μM hesperidin
for 48 h and 72 h, or negative controls) were centrifuged at
200×g for 10 min. After removal of the supernatants, cell
pellets were resuspended in 200 μl lysis buffer and incubated
for 30min at room temperature. The resulting cell lysates were
centrifuged at 200×g for 10 min after which 20 μl of the
supernatants was transferred to streptavidin-coated microtiter
plates. After a two hour incubation at room temperature, the
solutions were removed and each well was rinsed three times
with incubation buffer. Next, 100 μl ABTS solution (Roche
Life Sciences, Germany) was added to each well and incubat-
ed until color development was sufficient for photometric
analysis. Finally, 100 μl ABTS stop solution was added to
each well and color development was measured at 405 and
490 nm using an Elisa plate reader (Thermo Fisher Scientific,
Finland).
2.5 Caspase-3 enzyme activity assay
Changes in caspase-3 enzyme activity serve as important in-
dicators of apoptosis [32]. These changes were examined
using a caspase-3 colorimetric assay (BioVision Research
Products; San Francisco, CA, USA). Briefly, 5 × 105 A549
and MRC-5 cells (treated with 5–50 μM hesperidin for 48 h
and 72 h, or negative controls) were collected by centrifuga-
tion, lysed by adding 50 μl chilled Cell Lysis Buffer and
incubated on ice for 10 min before centrifugation. The
resulting supernatants were transferred to new tubes.
Next, reaction mixtures were prepared by adding 50 μl
Reaction Buffer, 50 μl sample and 5 μl DEVD-pNA
substrate, and incubated for 2 h. The reactions were
read at 405 nm as described above.
2.6 Mitochondrial membrane potential assay
We also examined loss of mitochondrial membrane potential
(MMP) in response to hesperidin treatment for 48 h in A549
and MRC-5 cells by JC-1 assay (Cayman Chemical, Ann
Arbor, MI, USA). Briefly, cells (5 × 105 cells/2 ml) were
collected by centrifugation at 1000 rpm for 10 min.
Supernatants were removed, pellets were homogenized in
200 μl medium, and 20 μl JC-1 dye was added to the cells.
Next, the cells were incubated at 37 °C in 5%CO2 for 30min,
centrifuged and, subsequently, 200 μl assay buffer was added
to the resulting pellets. All pellets were re-suspended in 320 μl
assay buffer and 100 μl of each of them was added to a 96-
well plate in triplicate. The plate was read using a fluorescence
Elisa plate reader (see above). Green/red (485 nm/560 nm)
values were calculated to determine changes in MMP.
2.7 Phosphatidylserine exposure and cell permeability assay
During apoptotic cell death, phosphatidylserine (PS), a phos-
pholipid component of the inner-leaflet of cell membranes
[32], becomes available at the cell surface. This early marker
of apoptotic cell death can be detected by staining with the
green fluorescent dye Annexin V-FITC (BD Pharmingen,
Germany). Briefly, 1 × 105/ml A549 and NCI-H358 cells
(treated with 5–50 μM hesperidin for 48 h, or negative con-
trols) were centrifuged, washed with HBSS (GIBCO,
Germany) and stained with 150 μl buffer containing 5 μl
Annexin V-FITC (1 mg/ml) and 1,5 μM 7-AAD at 37 °C.
After 10 min, 500 μl ice-cold buffer was added and the cells
were harvested by scraping off on ice. After centrifugation, the
resulting cells were re-suspended in 250 μl buffer and
analysed immediately using flow cytometry.
2.8 RNA extraction and microarray hybridization
Total RNA was isolated from A549, NCI-H358 and MRC-5
cells in response to 50 μM hesperidin treatment for 48 h using
a High Pure RNA Isolation Kit (Roche; Madison, WI, USA)
according to the manufacturer’s instructions. RNA concentra-
tions were determined using a NanoDrop (Thermo Fisher
Scientific) spectrophotometer (260 nm/280 nm ratios) and on-
ly the samples with an A260/A280 ratio between 1,9 and 2,1
were considered suitable for use. Illumina Human HT-12v4
beadchip microarrays containing 47,000 probes were used to
assess the global gene expression profiles for each sample
(Illumina, San Diego, CA, USA). Five hundred nanogram
total RNA was amplified, converted to cRNA, fragmented,
and biotin-labeled using an Illumina TotalPrep RNA-
amplification kit (Ambion; Foster City, CA, USA). Next, 1,
5 μg of labeled cRNA was hybridized to each microarray
according to the Illumina whole-genome gene expression di-
rect hybridization assay protocol, after which the microarrays
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were scanned using an Illumina BeadArray Reader. The im-
ages were processed and converted into signal intensities
using the Illumina GenomeStudio software package. The
same software package was used to perform hybridization
quality controls (QC).
2.9 Statistical analysis
Signal intensities corresponding to the gene expression levels
of individual microarrays were corrected for background
noise and imported into text files using the Illumina
GenomeStudio. Hierarchical cluster analysis was performed
on datasets to evaluate the Bproximity^ between the time
points. For data visualization, hierarchical clusters were con-
structed using the statistically significant (p < 0,05) genes. By
computing a p-value for each gene assessed, the statistical
significance of the differential expression of genes was deter-
mined. Genes were considered differentially expressed when
logarithmic gene expression ratios in three independent hy-
bridization experiments showed > 1,5-fold difference in ex-
pression level, and when the p-values were < 0,05. The Kyoto
Encyclopedia of Genes and Genomes (KEGG) and Ingenuity
Pathway Analysis (IPA; Ingenuity Systems, Redwood City,
CA, USA) tools, and gene ontology (GO) and pathway
Fig.1 Effects of hesperidin on cell proliferation (viability) and cytotoxicity.
Effects of hesperidin on proliferation and cytotoxicity of A549 (a–d),
NCI-H358 (b–e) and MRC-5 (c–f.) cells. WST-1 proliferation and LDH
cytotoxicity assays were performed using triplicate samples in three
independent experiments. Statistical significance was determined using
two-way analysis of variance, and p < 0.05 was considered significant
(* p < 0,05; ** p < 0,01).
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analyses were used to retrieve biological meanings of the dif-
ferentially expressed genes between the data points.
3 Results
3.1 Hesperidin inhibits the proliferation of A549
and NCI-H358 cells
To determine the anti-proliferative effects of hesperidin on
A549 and NCI-H358 non-small cell lung carcinoma
(NSCLC) cells and MRC-5 normal lung fibroblasts, the re-
spective cell lines were incubated with increasing concentra-
tions (5–50 μM) of hesperidin for 24, 48 and 72 h and, next,
subjected to a WST-1 colorimetric cell proliferation (viability)
assay. By doing so, we observed significant (p < 0,05) time-
and dose-dependent decreases in cell proliferation in the
NSCLC cell lines, but not in the control fibroblast cell line
nor in the non-treated control cells. The IC50 values of hes-
peridin for 24, 48 and 72 h were calculated from both cell
proliferation and cytotoxicity (see below) plots and estimated
to be 50 μM (Fig. 1a-c).
3.2 Hesperidin exerts a cytotoxic effect on A549
and NCI-H358 cells
To determine the cytotoxic effects of hesperidin on A549 and
NCI-H358 NSCLC cells and MRC-5 normal lung fibroblasts,
the respective cell lines were incubated with increasing con-
centrations (5–50μM) of hesperidin for 24, 48, 72 h and, next,
subjected to a LDH cytotoxicity assay (CytoTox 96R Non-
Radioactive Cytotoxicity Assay). Through this assay, we ob-
served significant (p < 0,05) time- and dose-dependent in-
creases in cytotoxicity compared to the control fibroblast cell
line and the non-treated control cells (Fig. 1d-f).
3.3 Hesperidin increases the apoptotic nucleosomal
enrichment factor
To quantify apoptotic cell death colorimetrically, A549 and
NCI-H358 NSCLC cells were incubated with 50 μM (see
above) hesperidin for 48 and 72 h, and changes in nucleoso-
mal enrichment factor (EF) were analyzed using a Cell Death
Detection ELISA PLUS assay (CDDE). We observed 5,15-
fold and 5,85-fold increases in EF after 48 and 72 h incubation
with 50 μM hesperidin in A549 cells, respectively, as com-
pared to the non-treated control cells (Fig. 2a; p < 0,05). In
analogy, we observed 6,55-fold and 7,06-fold increases in EF
in response to 48 and 72 h incubation with 50 μM hesperidin,
respectively, in NCI-H358 cells compared to the non-treated
control cells (Fig. 2b; p < 0,05).
3.4 Hesperidin increases apoptotic caspase-3 activity
To determine apoptotic effects of hesperidin on A549 NSCLC
cells and MRC-5 normal lung fibroblasts, the respective cell
lines were incubated with increasing concentrations of hesper-
idin for 48 h and changes in caspase-3 enzyme activities were
measured using a colorimetric assay kit (see matarials and
methods). We found a 1,19-fold increase in caspase-3 activity
after a 48 h incubation with 50 μM hesperidin in A549 cells,
as compared to non-treated control cells (Fig. 3; p < 0,05).
Under the same conditions, we found no change in caspase-3
activity in MRC-5 fibroblasts when compared to A549
NSCLC cells (Fig. 3). These results indicate that a dose-
dependent hesperidin-induced apoptosis of NSCLC cells
may be related to caspase-3 activity.
3.5 Hesperidin induces loss of mitochondrial membrane
potential
To assess the loss of mitochondrial membrane potential
(MMP), A549 NSCLC cells and MRC-5 normal lung fibro-
blasts were exposed to 50 μMhesperidin for 48 h, after which
Fig.2 Effects of hesperidin on apoptosis related nucleosomal enrichment
factors. Effects of hesperidin on apoptosis-related nucleosomal
enrichment factor of A549 (a) and NCI-H358 (b) cells. Cell Death
Detection Plus ELISA assays were performed using triplicate samples
in at least two independent experiments. Statistical significance was
determined using two-way analysis of variance, and p < 0.05 was
considered significant (* p < 0,05; ** p < 0,01)
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a JC-1 MMP assay was performed. This assay revealed a 1,
14-fold increase in loss of MMP in response to 50 μM hes-
peridin for 48 h in A549 cells, as compared to non-treated
control cells (Fig. 4; p < 0,05). Under the same conditions,
no significant MMP change in the MRC-5 cells was observed
when compared to A549 cells (Fig. 4).
3.6 Hesperidin causes translocation of PS from the inner
to the outer leaflet
FITC AnnexinV/PI double staining was performed in A549
and NCI-H358 NSCLC cells after exposure to 50 μM hesper-
idin for 48 h. The results of this assay indicate that a 48 h
incubation of A549 and NCI-H358 cells with 50 μM hesper-
idin increases apoptotic cell death compared to the non-treated
control group (Fig. 5a-d; p < 0,05).
3.7 Hesperidin induces changes in gene expression profiles
To reveal the cellular signaling pathways in NSCLC cells that
are affected by hesperidin treatment, we performed Illumina
Human HT-12v4 beadchip microarray-based whole-genome
expression profiling on A549 and NC-H358 NSCLC cells and
MRC-5 normal lung fibroblasts after 48 h hesperidin treat-
ment (50 μM). As an initial step, we analyzed the transcripts
that were most differentially expressed (i.e., most significant
p-values and fold-changes) and clustered the transcripts ac-
cording to their patterns of differential expression across the
samples. Then, we annotated biofunctions and performed
downstream effect analyses of hesperidin. To reveal biologi-
cally relevant networks beyond the canonical pathways, path-
way analyses were performed for the gene sets using IPA.
These networks indicate functional relationships between
gene products based on known interactions reported in the
literature (Fig. 6).
Through IPA analysis, three major goups of pathways
emerged in hesperidin treated A549 cells, i.e., cell signaling,
molecular transport, vitamin and mineral metabolism
(score = 44), cellular assembly, organization and molecular
transport (score = 35), and organ morphology and cellular
development (score = 35) pathways (supplemental Table 1).
In hesperidin treated NCI-H358 cells the major groups of
pathways were cell-to-cell signaling and interaction, cell-
mediated immune response and inflammatory response
(score = 35), cellular response to therapeutics (score = 35),
and organismal development, cell cycle, and cellular assembly
and organization (score = 32) pathways (supplemental
Table 2). In hesperidin treated MRC-5 cells the major
groups of pathways were cellular signaling and nucleic
acid metabolism (score = 36) and lipid metabolism and
molecular transport networks (score = 34) pathways
(supplemental Table 3).
Next, functional annotation analyses were performed com-
paring the hesperidin treated A549 and NCI-H358 NSCLC
cell lines. We clustered functional annotations of putative hes-
peridin targets using lung tumor, non-small lung cancer cells,
lung cancer and tumors, lung adenocarcinoma, and carcinoma
in lung as queries. By doing so, we found that genes in apo-
ptosis (p-value: 9,25E-13) and immune response (p-value: 3,
77E-12) pathways were most significantly affected in the hes-
peridin treated NSCLC cell lines (supplemental Table 4).
Based on further detailed pathway analyses, we found that
the FGF network genes FGF, PI3K, AKT, ERK and STATwere
differentially expressed in hesperidin treated A549 and NCI-
H358 cells (supplemental Fig.7). In addition, we found that
the NF-κB pathway genes IL-1, IL-1/TLR, PKCβ, RANKL
and BR3 were up-regulated, and the BMP 2/4, RAS and PI3K
genes were down-regulated, in NCI-H358 cells (supplemental
Fig. 8).
4 Discussion
Hesperidin is one of the most common flavanones and is
abundantly present in citrus fruits. Recent studies indicate that
hesperidin may exhibit cancer preventive and apoptotic effects
Fig. 3 Effects of hesperidin on caspase-3 activity in A549 and MRC-5
cells. Changes in caspase-3 enzyme activity in response to increasing
concentrations of hesperidin in A549 and MRC-5 cells. The results are
the means of two independent experiments. p < 0.05 was considered
significant
Fig. 4 Effects of hesperidin on membrane potential in A549 and MRC-5
cells. Loss of mitochondrial membrane potential (MMP) in response to
increasing concentrations of hesperidin in A549 and MRC-5 cells. The
results are represented as the means of two independent experiments.
p < 0.05 was considered significant
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[33]. The putative underlying mechanisms are, however, still
unknown. In the colon cancer cell line SNU-C4 it has been
shown that hesperidin can decrease cell viability by 65 %
compared to untreated cells [29]. Subsequent assessment of
the expression of apoptosis-regulating genes indicated that
hesperidin decreased the expression of BCL2 mRNA and in-
creased the expression of the BCL2-associated X (BAX) pro-
tein. The activity of the major apoptotic factor caspase-3 was
found to increase significantly upon hesperidin treatment, i.e.,
hesperidin down-regulated the expression of pro-caspase-3
and upregulated the level of active caspase-3. These results
suggest that hesperidin may induce apoptosis in human colon
cancer cells through caspase-3 activation [29]. Similarly,
Saiprasad et al. [35] showed that hesperidin can induce apo-
ptosis through modulating BCL2/BAX levels to increase the
activity of caspase-3 and caspase-9 in experimental colon can-
cer models. Furthermore, it has been found that hesperidin can
induce cell death in hepatocellular carcinoma HepG2 cells in a
caspase-independent manner by activating the ERK1/2 path-
way [36]. Taken together, these results indicate that hesperidin
may induce different cell death programs in different cancer
cell types.
Fig. 5 Effects of hesperidin on apoptosis. Effects of hesperidin (0 to
50 μM) on apoptosis in A549 (a–b) and NCI-H358 (c–d) cells. FITC
AnnexinV/PI double staining was used on cells treated with increasing
concentrations of hesperidin. Early apoptotic cells labeled with Annexin-
V but not PI (in lower right quadrant, Q4) and apoptotic cells labelled
with Annexin-V and PI (in upper right quadrant, Q2) are depicted in the
flow cytometric graphics. Necrotic cells are in quadrant Q1 The results
presented in b and d are means of two independent experiments. p < 0.05
was considered significant (* p < 0,05; ** p < 0,01)
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It has also been found that hesperidin can affect the prolif-
eration of MCF-7 breast cancer cells transfected with green
fluorescent protein (GFP)-coupled α-tubulin (MCF-7-GFP-
Tubulin), androgen-independent PC-3 and DU-145 prostate
Fig. 6 Functional analysis of genes selected through microarray-based
expression profiling. The functional network was algorithmically
constructed using Ingenuity Pathway Analysis (IPA) software on the
basis of the functional and biological connectivity of genes in A549 (a),
NCI-H358 (b) andMRC-5 (c) cells. The top-scoring genes regulated after
48 h of 50 μM hesperidin treatment, where Gpcr (a, c) and IFN-γ (b) are
central nodes generated by the IPA software, are shown. Red and green
represent up- and down-regulated genes, respectively, based on fold
change as compared to non-treated samples
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cancer cells, and androgen-dependent LNCaP prostate cancer
cells [34]. Specifically, hesperidin was found to inhibit the
proliferation of MCF-7-GFP-Tubulin cells, most likely inde-
pendent of an anti-mitotic mechanism. Hesperidin was also
found to inhibit basal and testosterone-induced proliferation
of LNCaP cells, whereas it did not significantly affect the
proliferation of androgen-independent prostate cancer cells
(PC-3 and DU-145). Based on these data, the authors conclud-
ed that further research on possible functional interactions
between hesperidin and androgen receptors, including their
downstream signaling pathways, is warranted [34].
Our data are in line with previous studies indicating that
hesperidin may have growth inhibitory and apoptotic effects
in cancer cells. Specifically, we found that hesperidin has a
growth inhibitory effect and triggers the apoptotic pathway in
two NSCLC cell lines (A549 and NCI-H358 cells) in a time-
and dose-dependent manner. We also observed a very low
cytotoxic effect of hesperidin in normal lung fibroblasts
(MRC-5). Hesperidin was found to increase the caspase-3
enzyme level and to induce loss of mitochondrial membrane
potential (MMP), which are important indicators of apoptosis,
in a time- and dose-dependent manner. FITC AnnexinV/PI
double staining confirmed the apoptotic effects of hesperidin
on the NSCLC cells tested.
Citrus flavonoids may act in concert with known chemo-
therapeutic agents. It has e.g. been reported that hesperidin
treatment of Ramos Burkitt’s lymphoma cells can abrogate
constitutive and doxorubicin-induced NF-κB activation
through inhibition of phosphorylation of its inhibitory subunit
(IκB), and that hesperidin treatment can result in inhibition of
proliferation and induction of apoptosis in a PPARγ-
independent manner [31]. In another study, Ghorban et al.
reported that hesperidin can induce the expression and tran-
scriptional activity of PPARc, promote p53 accumulation and
downregulate constitutive NF-κB activity in a PPARγ-
dependent and PPARγ-independent manner in the pre-B cell
line NALM-6 [30]. The growth-inhibitory effect of hesperidin
was partially reduced when the NALM-6 cells were incubated
with a PPARγ antagonist prior to the exposure to hesperidin.
The findings of this latter study clearly demonstrate that
hesperidin-mediated pro-apoptotic and anti-proliferative ac-
tions are regulated via both PPARγ-dependent and PPARγ-
independent pathways in NALM-6 cells. Together, these data
indicate that hesperidin has a potential to be developed into a
therapeutic agent for hematologic malignancies.
In order to determine signaling networks and pathways
regulated by hesperidin in NSCLC cells, we performed
microarray-based expression profiling. By doing so, we found
that inflammatory response pathways, including the FGF and
NF-κB signal transduction pathways, were most significantly
affected in the NCI-H358 and A549 NSCLC cells tested.
Taken together, we conclude that hesperedin elicits a growth
inhibitory effect on NSCLC cells by modulating immune
response-related pathways that affect apoptosis. As such,
hesperidin may serve as a novel anti-proliferative agent for
non-small cell lung cancer.
Acknowledgments This work was funded by Istanbul University Sci-
entific Research Project number 9205. We would like to thank Mr. David
Chapman for editing the manuscript.
Conflict of interest The authors declare that they have no conflict of
interest.
References
1. W. Pao, N. Girard, New driver mutations in non-small-cell lung can-
cer. Lancet Oncol. 12, 175–180 (2011)
2. W.D. Travis, Classification of lung cancer. Semin. Roentgenol. 46,
178–186 (2011)
3. Q.Wu, Y.F. Chen, J. Fu, Q.H. You, S.M.Wang, X. Huang, X.J. Feng,
S.H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-
A attenuates the aggressive phenotype of lung adenocarcinoma cells.
Cell. Oncol. 37, 399–407 (2014)
4. A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological
and clinical perspective. Cell. Oncol. 36, 265–275 (2013)
5. N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M.
Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like
growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the
tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell.
Oncol. 36, 277–288 (2013)
6. A. Maier, AL. Peille, V. Vuaroqueaux, M. Lahn. Anti-tumor activity
of the TGF-β receptor kinase inhibitor galunisertib (LY2157299
monohydrate) in patient-derived tumor xenografts. Cell. Oncol.
2015 Jan 9. [Epub ahead of print] DOI 10.1007/s13402-014-0210-8
7. P. Ulivi, R. Silvestrini, Role of quantitative and qualitative character-
istics of free circulating DNA in the management of patients with
non-small cell lung cancer. Cell. Oncol. 36, 439–448 (2013)
8. G. Giaccone, Twenty-five years of treating advanced NSCLC: what
have we achieved? Ann. Oncol. 15 Suppl 4: iv81–83 (2004)
9. J.W. Neal, L.V. Sequist, Exciting new targets in lung cancer therapy:
ALK, IGF-1R, HDAC, and Hh. Curr. Treat. Options in Oncol. 11,
36–44 (2010)
10. R. Sangha, P.N. Lara, P.C. Mack, D.R. Gandara, Beyond
antiepidermal growth factor receptors and antiangiogenesis strategies
for nonsmall cell lung cancer: exploring a new frontier. Curr. Opin.
Oncol. 21, 116–123 (2009)
11. S. Mateen, K. Raina, R. Agarwal, Chemopreventive and anti-cancer
efficacy of silibinin against growth and progression of lung cancer.
Nutr. Cancer J. 65, 3–11 (2013)
12. J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside,
as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784
(2011)
13. T. Tanaka, R. Takahashi, Flavonoids and asthma. Nutrients 10, 2128–
2143 (2013)
14. J.A. Manthey, K. Grohmann, N. Guthrie, Biological properties of
citrus flavonoids pertaining to cancer and inflammation. Curr. Med.
Chem. 8, 135–153 (2001)
15. J. Yu, L. Wang, R.L. Walzem, E.G. Miller, L.M. Pike, B.S. Patil,
Antioxidant activity of citrus limonoids, flavonoids, and coumarins.
J. Agric. Food Chem. 53, 2009–2014 (2005)
16. S.L. Hwang, P.H. Shih, G.C. Yen, Neuroprotective effects of citrus
flavonoids. J. Agric. Food Chem. 60, 877–885 (2012)
Effects of hesperidin in non-small cell lung cancer cells 203
17. E.Meiyanto, A. Hermawan, Anindyajati: natural products for cancer-
targeted therapy: citrus flavonoids as potent chemopreventive agents.
Asian. Pac. J. Cancer Prev. 13, 427–1436 (2012)
18. J.A. Manthey, N. Guthrie, Antiproliferative activities of citrus flavo-
noids against six human cancer cell lines. J. Agric. Food Chem. 50,
5837–5843 (2002)
19. G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin
alleviates oxidative stress and downregulates the expressions of pro-
liferative and inflammatorymarkers in azoxymethane-induced exper-
imental colon carcinogenesis in mice. Inflamm. Res. 62, 425–440
(2013)
20. O.G. Benavente, J. Castillo, M. Alcaraz, V. Vicente, J.A. Del, A.
Ortuno, Beneficial action of Citrus flavonoids on multiple cancer-
related biological pathways. Curr. Cancer Drug Targets 7, 795–809
(2007)
21. J. Nones, T.C.E. Spohr, F.C. Gomes, Hesperidin, a flavone glycoside,
as mediator of neuronal survival. Neurochem. Res. 36, 1776–1784
(2011)
22. V. Gaur, A. Kumar, Hesperidin pre-treatment attenuates NO-
mediated cerebral ischemic reperfusion injury and memory dysfunc-
tion. Pharmacol. Rep. 62, 635–648 (2010)
23. S. Ou, Pharmacological action of hesperidin. Zhong. Yao. Cai. 25,
531–533 (2002)
24. O. Benavente-Garcia, J. Castillo, Update on uses and properties of
citrus flavonoids: new findings in anticancer, cardiovascular, and
anti-inflammatory activity. J. Agric. Food Chem. 56, 6185–6205
(2008)
25. A. Chanet, D. Milenkovic, C. Manach, A. Mazur, C. Morand, Citrus
flavanones: what is their role in cardiovascular protection? J. Agric.
Food Chem. 60, 8809–8822 (2012)
26. B.D. Sahu, M. Kuncha, G.J. Sindhura, R. Sistla, Hesperidin attenuates
cisplatin-induced acute renal injury by decreasing oxidative stress, in-
flammation and DNA damage. Phytomedicine 20, 453–460 (2013)
27. J.R. Patil, K.N. Chidambara Murthy, G.K. Jayaprakasha, M.B.
Chetti, B.S. Patil, Bioactive compounds from Mexican lime [Citrus
aurantifolia] juice induce apoptosis in human pancreatic cells. J.
Agric. Food Chem 57, 10933–10942 (2009)
28. M. Galleano, O. Pechanova, C.G. Fraga, Hypertension, nitric oxide,
oxidants, and dietary plant polyphenols. Curr. Pharm. Biotechnol. 11,
837–848 (2010)
29. H.J. Park, M.J. Kim, E. Ha, J.H. Chung, Apoptotic effect of hesper-
idin through caspase3 activation in human colon cancer cells, SNU-
C4. Phytomedicine 15, 147–151 (2008)
30. A. Ghorban, M. Nazari, M. Jeddi-Tehrani, H. Zand, The citrus flavo-
noid hesperidin induces p53 and inhibits NF-κB activation in order to
trigger apoptosis in NALM-6 cells: involvement of PPARγ-
dependent mechanism. Eur. J. Nutr. 51, 39–46 (2012)
31. M. Nazari, A. Ghorbani, A. Hekmat-Doost, M. Jeddi-Tehrani, H.
Zand, Inactivation of nuclear factor-κB by citrus flavanone hesperi-
din contributes to apoptosis and chemo-sensitizing effect in Ramos
cells. Eur. J. Pharmacol. 650, 526–533 (2011)
32. K. Mohankumar, S. Pajaniradje, S. Sridharan, V.K. Singh, L.
Ronsard, A.C. Banerjea, B.C. Selvanesan, M.S. Coumar, L.
Periyasamy, R. Rajagopalan, Apoptosis induction by an analog of
curcumin (BDMC-A) in human laryngeal carcinoma cells through
intrinsic and extrinsic pathways. Cell. Oncol. 37, 439–454 (2014)
33. S. Aranganathan, N. Nalini, Efficacy of the potential chemopreven-
tive agent, hesperetin [citrus flavanone], on 1,2-dimethylhydrazine
induced colon carcinogenesis. Food Chem. Toxicol. 47, 2594–2600
(2009)
34. C.J. Lee, L. Wilson, M.A. Jordan, V. Nguyen, J. Tang, G. Smiyun,
Hesperidin suppressed proliferations of both human breast cancer and
androgen-dependent prostate cancer cells. Phytother. Res. Suppl 1,
S15–S19 (2010)
35. G. Saiprasad, P. Chitra, R. Manikandan, G. Sudhandiran, Hesperidin
induces apoptosis and triggers autophagic markers through inhibition
of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian
target of rapamycin and glycogen synthase kinase-3 beta signalling
cascades in experimental colon carcinogenesis. Eur. J. Cancer 50,
2489–2507 (2014)
36. S. Yumnam, HS. Park,MK. Kim, A. Nagappan, GE. et al, Hesperidin
induces paraptosis like cell death in hepatoblatoma, HepG2 cells:
involvement of ERK1/2 MAPK. PLoS One 30;9(6):e101321 (2014)
204 Z.B. Cincin et al.
